全球乙型肝炎相关肝病负担:2000至2021年间全球超过三分之一国家慢性HBV感染所致原发性肝癌发病率上升
基于2021年全球疾病负担研究数据,评估急性HBV感染、HBV相关肝硬化和HBV相关肝癌的患病率、发病率与死亡率。HBV相关原发性肝癌占全球原发性肝癌发病的39%。2000至2021年间,HBV相关肝病的年龄标化发病率、患病率和死亡率下降,但HBV相关原发性肝癌发病率在65个国家上升。
要点
- 西太平洋地区HBV相关原发性肝癌发病率最高,为5.24/10万,死亡率为4.38/10万。
- 2000至2021年,HBV相关原发性肝癌年龄标化患病率在欧洲(年度百分比变化0.77%,95%CI 0.72%-0.81%)和美洲(年度百分比变化1.05%,95%CI 1.00%-1.10%)上升。
核心结论
- 2000至2021年间HBV相关肝病发病率和患病率下降,但超过三分之一国家HBV相关原发性肝癌发病率上升,提示需加强HBV治疗以降低肝癌风险。
研究设计与样本
- 基于2021年全球疾病负担研究数据,评估急性HBV感染、HBV相关肝硬化和HBV相关肝癌的患病率、发病率与死亡率。
主要发现
- HBV相关原发性肝癌占全球原发性肝癌发病的39%。
- 西太平洋地区HBV相关原发性肝癌发病率最高,为5.24/10万,死亡率为4.38/10万。
- 2000至2021年间,HBV相关肝病的年龄标化发病率、患病率和死亡率下降,但HBV相关原发性肝癌发病率在65个国家上升。
- HBV相关原发性肝癌年龄标化患病率在欧洲年度百分比变化为0.77%(95%CI 0.72%-0.81%),在美洲为1.05%(95%CI 1.00%-1.10%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS AND AIMS: HBV-related liver disease ranks as the seventh leading cause of mortality. Despite advances in prevention and treatment, global disparities in the burden of primary liver cancer (PLC) persist. We evaluate global trends in the prevalence, incidence, and death of HBV-related liver disease. APPROACH AND RESULTS: Data from the Global Burden of Disease Study 2021 evaluated acute HBV infection, HBV-related cirrhosis, and HBV-related liver cancer prevalence, incidence, and death. In 2021, there were 7.30 million cases of acute HBV, 283.64 million cases of HBV-related cirrhosis, and 288,110 cases of HBV-related PLC. HBV-related PLC accounted for 39% of the global incidence of PLC; Western Pacific had the highest rates for HBV-related PLC, with an incidence of 5.24 and a death rate of 4.38 per 100,000 population. Between 2000 and 2021, age-standardized incidence, prevalence, and death rates from HBV-related liver disease decreased; however, the incidence of HBV-related PLC rose in 65 countries from 2000 to 2021. In parallel, age-standardized prevalent rates from HBV-related PLC increased in Europe (annual percent change: 0.77%, 95% CI: 0.72%-0.81%) and the Americas (annual percent change: 1.05%, 95% CI: 1.00%-1.10%). CONCLUSIONS: From 2000 to 2021, decreases in HBV-related liver disease incidence and prevalence were observed; however, more than one-third of countries showed an increase in the incidence of HBV-related PLC. These findings highlight the need for strengthened HBV treatment efforts to reduce the risk of liver cancer.
引用
- Danpanichkul P, Duangsonk K, Chen VL, et al. Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021. Hepatology. 2025. PMID: 39937958. doi:10.1097/HEP.0000000000001260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。